



Diagnósticos da América S.A.

Investor Relations
Av. Juruá, 434 - Alphaville, Barueri - SP
55 11 4197-5410
55 11 4197-5509
ir@danet.com.br
www.diagnosticosdaamerica.com.br



MATERIAL FACT

Diagnósticos da América S.A.
Publicly Held Company
Corporate taxpayer's ID (CNPJ/MF) 61.486.650/0001-83

Pursuant to CVM Instruction 358/2002 and the current legislation, Diagnósticos da América S.A. (Bovespa: DASA3), informs its shareholders and to the market that:

On August 29, 2007, Diagnósticos da América S. A. ("DASA") acquired 1,109,203 quotas representing 100% of the capital stock of MED IMAGEM ULTRA-SONOGRAFIA E RADIOLOGIA LTDA. ("MedImagem"), a company that provides imaging services in the cities of Niterói, São Gonçalo and Rio de Janeiro, in Rio de Janeiro state.

The firm was valued at R\$ 47.0 million, where R\$ 2.3 million refers to the net debt assumed. Of the remaining amount R\$ 30.3 million will be paid to MedImagem's former partners at closing and R\$ 4.5 million after one year. The amount of R\$ 10.0 million will be retained in an escrow account for up to 6 years.

MedImagem is the largest imaging company in Niterói, Rio de Janeiro State. Founded in 1992, it operates 8 PSCs, being six in Niterói, one in São Gonçalo (Niterói surroundings) and one in Copacabana (Rio de Janeiro). The clinic has a highly qualified medical team composed by 67 physicians, which has been helping to build a strong reputation among the local community.

With MedImagem's acquisition, DASA intends to leverage its presence in Niterói's and São Gonçalo's regions as well as to complement its multiproduct strategy in Rio de Janeiro, increasing imaging services revenues by more than 100%. The expansion plan forecasts the introduction of new imaging tests and opening of new PSCs, as well as the integration with the reporting central in Rio de Janeiro and also expansion to nearby cities: São Gonçalo, Região dos Lagos, Cabo Frio e Macaé.

This deal was approved on a meeting held on August 29th, 2007 by DASA's Board of Directors. Because the purchase price does not represent a significant investment for DASA as per Act no. 6.404/76, Article 256, Subsection I, Paragraph 1, and this transaction does not have to be submitted to a Special Shareholders' Meeting for ratification. The acquisition of MedImagem will also be submitted to the Brazilian Antitrust Commission (CADE) for approval.

São Paulo, August 30, 2007

Marcelo Marques Moreira Filho
Chief Executive Officer

